Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results...
United States Carl Spana Palatin Technologies Inc Prnewswire Palatin Technologies Inc Securities Exchange Dry Eye Disease Ongoing
Source: prnewswire.com